Join Growin Stock Community!
Beta
Back to LLY.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • Revenue by Segments
  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
eps-chart

LLY EPS

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

The latest data point for Eli Lilly's (LLY) EPS in Q1'26 stands at 8.27 USD, marking a significant increase from the previous quarter's 7.4 USD in Q4'25 and reflecting robust profitability growth over the fiscal period covered from Q2'23 to Q1'26. Over this timeframe, EPS exhibits an overall upward trend with notable volatility, starting at 1.96 USD in Q2'23, dipping to a low of -0.06 USD in Q3'23 due to potential one-time factors, and then steadily climbing to highs above 8 USD by Q1'26, driven by consistent year-over-year growth rates averaging around 50-100% in recent quarters, such as 169% in Q1'26; the EPS Growth (YoY) line reinforces this momentum, fluctuating between negative and over 19% but trending positively, highlighting LLY's strengthening financial performance amid pharmaceutical sector dynamics.